Navigation Links
Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
Date:2/27/2008

TOKYO, Feb. 27 /PRNewswire/ -- Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States), its wholly owned U.S. subsidiary, received on February 25, 2008 (local time) a Not approvable letter from the U.S. Food and Drug Administration (FDA) for istradefylline (KW-6002), its investigational drug for the treatment of Parkinson's disease.

In the not approvable letter FDA expressed concern if the efficacy findings support clinical utility of istradefylline (KW-6002). FDA requested an overall summary of nonclinical mineralization findings. Additionally, FDA asked for clinical pharmacology follow-up information as a Phase 4 commitment.

After closely examining the FDA's response, Kyowa Hakko will work closely with FDA and conduct a comprehensive discussion to determine a path forward for istradefylline (KW-6002).

Istradefylline (KW-6002) has a novel mechanism of action that antagonizes the adenosine A2A receptor. It has been under FDA review as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.

Kyowa Hakko is a biotechnology-based company focused on two businesses: pharmaceutical operations engaged in the research and development, manufacturing, and marketing of prescription drugs; and bio-chemical operations that handle a variety of products such as amino acids, nucleic acids, and nutritional supplements/healthcare products. Its pharmaceutical business places emphasis on research and development in the fields of oncology, allergy, and the central nervous system. In Japan, Kyowa Hakko is marketing medications for a wide range of diseases, including allergy, hypertension, angina pectoris, and cancer. With the aim of penetrating the global market, Kyowa Hakko has overseas development bases in the U.S. (Kyowa Pharmaceutical, Inc. and BioWa, Inc.) an
'/>"/>

SOURCE Kyowa Hakko Kogyo Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property development ... intellectual property, announced today that the Markman hearing ... the U.S. District Court for the Northern District ... rescheduled for November 10, 2014.  This hearing was ... Order setting the Markman date was received after ...
(Date:10/1/2014)... September 30, 2014 The participants committed ... but to spending their own time adjusting, tweaking and ... complex designs were ready for judging. , “I enjoyed ... firm thought leader. “The entries showed a commendable ... physical characteristics of the print medium and the creativity ...
(Date:10/1/2014)... New applications of structures and materials ... in nature over millennia are featured in a ... applications in biophotonics in the October issue of the ... published by SPIE, the international society for optics and ... peer-reviewed articles are accessible via open access. , “Biomimetic ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Dec. 13 BioMed Realty Trust, Inc.,(NYSE: BMR ... to its,board of directors, increasing the board to eight ... real estate industry, with a breadth of,ability and experience ... real estate projects. We believe that,Rick,s contributions to our ...
... new validation studies,were published during 2007 on the ... number of studies published to 65., "This ... interest from US and,European institutes" said Gary Zamler, ... academic medical institutions and teaching hospitals,have completed studies ...
... retired $12.83 million in existing current 2008 convertible notes, and extended the ... ... convertible notes, SEATTLE, Dec. 13 Cell Therapeutics, Inc.,("CTI" or the ... of its new 5.75% Convertible Senior,Notes (the "New Notes") due 2011 and ...
Cached Biology Technology:BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 32007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3
(Date:10/1/2014)... to take a healthy salad up a level by ... cancer in leafy greens. , "In the long run, ... eating the salad or making a pill from the ... engineering at Case Western Reserve School of Medicine and ... breast cancer organization is funding the research with a ...
(Date:10/1/2014)... 2014 Neuartiger Detektionstechnologie ... Die Biowissenschaften erlebten in den ... Detektionstechnologien. Einige davon sind Senkrechtstarter und andere ... ist eine neuartige Detektionstechnologie, die von Forschern ... wurde. Jetzt ist diese Technologie endlich auf ...
(Date:10/1/2014)... , October 1, 2014 ... the life science field  The life ... and go over the years. Some are shooting ... upconversion is a novel detection technology that has ... Now, finally, this technology is becoming commercially available. ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... For those living with gastrointestinal disorders, such as ulcers or ... or dietary changes. But what if one day treatment meant ... free of inflamed or diseased tissues? That is ... Institute of Technology (MIT) are hoping their new study findings ...
... The winners of NERC,s inaugural short article and photography ... London this evening. The winning essay, by Laura ... excitement she felt during a recent research voyage when ... black smoke across her monitoring screens. These are underwater ...
... the 20th International AIDS Conference (AIDS 2014) to be ... today announced 19 major plenary presentations, focusing on the primary ... sessions will open each day of the conference, which is ... 200 countries. "We are excited to have such ...
Cached Biology News:Manufacturing a new gut to treat GI diseases 2NERC announces the winner of its first photo and essay competition 2NERC announces the winner of its first photo and essay competition 320th International AIDS Conference (AIDS 2014) plenary speakers announced 220th International AIDS Conference (AIDS 2014) plenary speakers announced 3
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
...
... sufficient materials for 1,464 array sample elements. , ... , Blocker BSA in PBS (10X): 50 ... 10 g , BupH Phosphate Buffered ... 2 x 10 ml ampules , SuperSignal West ...
... Obtain Clean and Accurate Results Laser ... increase the sensitivity and accuracy of molecular ... cell types and multi-cellular structures isolated from ... approach to microdissection-developed in 1996 at the ...
Biology Products: